Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Rating) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,498.43 ($18.26) and traded as high as GBX 1,760.50 ($21.46). Hikma Pharmaceuticals shares last traded at GBX 1,741.50 ($21.22), with a volume of 250,990 shares traded.
Analysts Set New Price Targets
HIK has been the subject of several research analyst reports. JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 2,100 ($25.59) price objective on shares of Hikma Pharmaceuticals in a research report on Thursday, March 9th. Royal Bank of Canada boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,750 ($21.33) to GBX 1,950 ($23.77) and gave the stock an “outperform” rating in a research report on Wednesday, March 1st. Citigroup restated a “buy” rating and issued a GBX 1,920 ($23.40) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, January 31st. Berenberg Bank lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,440 ($17.55) to GBX 1,740 ($21.21) and gave the stock a “hold” rating in a report on Friday, February 24th. Finally, Barclays lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,650 ($20.11) to GBX 1,700 ($20.72) and gave the stock an “equal weight” rating in a report on Friday, February 24th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Hikma Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,882 ($22.94).
Hikma Pharmaceuticals Stock Up 0.1 %
The company has a market cap of £3.84 billion, a price-to-earnings ratio of 2,523.91, a price-to-earnings-growth ratio of 2.38 and a beta of 0.31. The company has a current ratio of 1.86, a quick ratio of 1.27 and a debt-to-equity ratio of 59.73. The firm’s fifty day moving average price is GBX 1,726.62 and its 200-day moving average price is GBX 1,498.43.
Hikma Pharmaceuticals Increases Dividend
In other news, insider Deneen Vojta purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The stock was bought at an average price of GBX 1,703 ($20.76) per share, with a total value of £17,030 ($20,755.64). 29.63% of the stock is owned by company insiders.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.